Nombre del producto:3-((2-Chloropyridin-4-yl)oxy)-6-iodo-2-methylpyridine

IUPAC Name:3-[(2-chloropyridin-4-yl)oxy]-6-iodo-2-methylpyridine

CAS:1628184-06-4
Fórmula molecular:C11H8ClIN2O
Pureza:98%
Número de catálogo:CM535948
Peso molecular:346.55

Unidad de embalaje Stock disponible Precio($) Cantidad
CM535948-100mg in stock ȡŵǜ
CM535948-250mg in stock ŵȡȐ
CM535948-1g in stock ũŵȐ
CM535948-5g 1-2 Weeks ȡŵǜȺ
CM535948-10g 1-2 Weeks ŵȡȐư

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :1628184-06-4
Fórmula molecular:C11H8ClIN2O
Punto de fusión:-
Código de sonrisas:CC1=NC(I)=CC=C1OC2=CC(Cl)=NC=C2
Densidad:
Número de catálogo:CM535948
Peso molecular:346.55
Punto de ebullición:
Nº Mdl:
Almacenamiento:Store at room temperature

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Vimseltinib
Vimseltinib (DCC-3014) is a potent and highly selective oral CSF1R kinase inhibitor that selectively and effectively inhibits CSF1R by utilizing the unique characteristics of the switch control region that regulates kinase conformational activation. The key phase 3 MOTION study conducted by vimseltinib in patients with giant cell tumor of the tendon sheath (TGCT) has shown positive results, and it is expected to submit a listing application to the FDA and the European Union next year.

Related Products